[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1995003406A3 - Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens - Google Patents

Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens Download PDF

Info

Publication number
WO1995003406A3
WO1995003406A3 PCT/US1994/008334 US9408334W WO9503406A3 WO 1995003406 A3 WO1995003406 A3 WO 1995003406A3 US 9408334 W US9408334 W US 9408334W WO 9503406 A3 WO9503406 A3 WO 9503406A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotide
multiplication
cell proliferation
protein production
enhancement
Prior art date
Application number
PCT/US1994/008334
Other languages
French (fr)
Other versions
WO1995003406A2 (en
WO1995003406A9 (en
Inventor
Nanibhushan Dattagupta
C Nagaraja Sridhar
Daniel L Kacian
Original Assignee
Gen Probe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Probe Inc filed Critical Gen Probe Inc
Priority to KR1019960700257A priority Critical patent/KR960704034A/en
Priority to EP94925685A priority patent/EP0781332A2/en
Priority to JP7505358A priority patent/JPH09500787A/en
Priority to AU75505/94A priority patent/AU689129B2/en
Publication of WO1995003406A2 publication Critical patent/WO1995003406A2/en
Publication of WO1995003406A9 publication Critical patent/WO1995003406A9/en
Publication of WO1995003406A3 publication Critical patent/WO1995003406A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention features the use of a purified first targeted oligonucleotide in combination with either 1) a subtargeted oligonucleotide, 2) second targeted oligonucleotide, or 3) a non-targeted phosphorothioate oligonucleotide, to inhibit protein production of a targeted nucleic acid sequence, cell proliferation, and/or the multiplication of a foreign organism. The subtargeted oligonucleotide contains a truncated version of the targeted oligonucleotide.
PCT/US1994/008334 1993-07-19 1994-07-19 Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens WO1995003406A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1019960700257A KR960704034A (en) 1993-07-19 1994-07-19 Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and / or Multiplication of Infectious Disease Pathogens
EP94925685A EP0781332A2 (en) 1993-07-19 1994-07-19 Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
JP7505358A JPH09500787A (en) 1993-07-19 1994-07-19 Promoting inhibition of oligonucleotides on protein production, cell growth and / or growth of infectious disease pathogens
AU75505/94A AU689129B2 (en) 1993-07-19 1994-07-19 Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9380093A 1993-07-19 1993-07-19
US08/093,800 1993-07-19

Publications (3)

Publication Number Publication Date
WO1995003406A2 WO1995003406A2 (en) 1995-02-02
WO1995003406A9 WO1995003406A9 (en) 1995-03-02
WO1995003406A3 true WO1995003406A3 (en) 1995-09-14

Family

ID=22240803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/008334 WO1995003406A2 (en) 1993-07-19 1994-07-19 Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens

Country Status (6)

Country Link
EP (1) EP0781332A2 (en)
JP (1) JPH09500787A (en)
KR (1) KR960704034A (en)
AU (1) AU689129B2 (en)
CA (1) CA2166890A1 (en)
WO (1) WO1995003406A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888325B2 (en) 1999-01-28 2011-02-15 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US9051566B2 (en) 2001-01-31 2015-06-09 Alnylam Pharmaceuticals, Inc. Post-transcriptional gene silencing using expressed double stranded RNA
US9102939B2 (en) 1997-12-23 2015-08-11 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003407A2 (en) * 1993-07-19 1995-02-02 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US5674995A (en) * 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
CA2222520A1 (en) * 1995-06-07 1996-12-19 Yathi M. Naidu Oligonucleotides specific for cytokine signal transducer gp130 mrna
US5747470A (en) * 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
CA2513336A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd. Control of gene expression in a non-human eukaryotic cell, tissue or organ
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
DE102004038535B4 (en) * 2004-08-06 2012-10-04 Universitätsklinikum Schleswig-Holstein Cellular introduction of nucleic acid agents
PL2056845T3 (en) 2006-08-08 2018-01-31 Univ Bonn Rheinische Friedrich Wilhelms Structure and use of 5' phosphate oligonucleotides
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288163A2 (en) * 1987-03-25 1988-10-26 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Oligodeoxynucleotides as inhibitors of the replication of retroviruses and the expression of oncogenes
EP0318245A2 (en) * 1987-11-24 1989-05-31 Gen-Probe Incorporated Means and method for enhancing nucleic acid hybridization
WO1992014843A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
WO1993015194A1 (en) * 1992-02-04 1993-08-05 Worcester Foundation For Experimental Biology Enhancement of ribozyme catalytic activity by a neighboring facilitator oligonucleotide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288163A2 (en) * 1987-03-25 1988-10-26 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Oligodeoxynucleotides as inhibitors of the replication of retroviruses and the expression of oncogenes
EP0318245A2 (en) * 1987-11-24 1989-05-31 Gen-Probe Incorporated Means and method for enhancing nucleic acid hybridization
WO1992014843A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
WO1993015194A1 (en) * 1992-02-04 1993-08-05 Worcester Foundation For Experimental Biology Enhancement of ribozyme catalytic activity by a neighboring facilitator oligonucleotide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. MAJUMDAR ET AL.: "Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide", BIOCHEMISTRY, vol. 28, pages 1340 - 1346 *
J. GOODCHILD: "Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitatot) and by 2'-O-methylation", NUCLEIC ACIDS RESEARCH, vol. 20, no. 17, pages 4607 - 4612 *
J.M. BURKE ET AL.: "In vitro selection and evolution of RNA...", FASEB JOURNAL, vol. 7, no. 1, pages 106 - 112 *
L.J. MAHER III ET AL.: "Comparative hybrid arrest by tandem antisense oligodeoxyribonucleotides or oligodeoxyribonucleotide methylphosphonates in a cell-free system", NUCLEIC ACIDS RESEARCH, vol. 16, no. 8, pages 3341 - 3358 *
R.B. DENMAN: "Cleavage of full length APP mRNA by mannerhead ribozymes", NUCLEIC ACIDS RESEARCH, vol. 21, no. 17, pages 4119 - 4125 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102939B2 (en) 1997-12-23 2015-08-11 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US7888325B2 (en) 1999-01-28 2011-02-15 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US8148345B2 (en) 1999-01-28 2012-04-03 Georgia Health Sciences University Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US9051566B2 (en) 2001-01-31 2015-06-09 Alnylam Pharmaceuticals, Inc. Post-transcriptional gene silencing using expressed double stranded RNA

Also Published As

Publication number Publication date
EP0781332A2 (en) 1997-07-02
WO1995003406A2 (en) 1995-02-02
AU7550594A (en) 1995-02-20
AU689129B2 (en) 1998-03-26
JPH09500787A (en) 1997-01-28
CA2166890A1 (en) 1995-02-02
KR960704034A (en) 1996-08-31

Similar Documents

Publication Publication Date Title
WO1995003406A3 (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
CA2210353A1 (en) Stabilized external guide sequences
DE69400208D1 (en) Olionukleotidalkylphosphonate und -phosphonothioate
AU6589094A (en) 7-deazapurine modified oligonucleotides
CA2165821A1 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
BG101103A (en) Mammalian telomerase
WO1995006731A3 (en) Non-nucleotide containing enzymatic nucleic acid
NO954217L (en) Guanosine-rich antivirus oligonucleotides
ATE174599T1 (en) BINDING COMPETENT OLIGOMERS CONTAINING 2',5' BONDS
BR9401355A (en) Oligonucleotide and nucleotide.
CY1106978T1 (en) PHOSPHOSESTERATION ENZYME
AU7623194A (en) Oligonucleotides with rna cleavage activity
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
CA2340934A1 (en) Novel collectin
AU3698297A (en) Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy
MX9806041A (en) PURIFIED SR-p70 PROTEIN.
AU6144294A (en) Plant virus resistance conferring polyribozyme and resistant plants producing same
WO2000027880A3 (en) Rantes-derived peptides with anti-hiv activity
WO1994028176A3 (en) Bc200 rna, probes therefor and use thereof
WO1999064451A3 (en) Plant protein with repeated wd40 motifs, nucleic acid coding for said protein, and uses thereof
CA2287902A1 (en) Isolated nucleic acid molecules encoding ssx family members and uses thereof
CA2475337A1 (en) Methods for cultivating cells and propagating viruses
MX9708877A (en) 'delta'p62, variants thereof, nucleic acid sequences and uses thereof.
UA9689A (en) Inducer of interferon type i in humans and animals
EP1004672A3 (en) Thermostable protein having deoxyribonuclease activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGE 42,DESCRIPTION,REPLACED BY NEW PAGE 42;AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2166890

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994925685

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994925685

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994925685

Country of ref document: EP